Traci McCarty | Vice President, Investor Relations |
Jean-Jacques Bienaimé | Chairman and Chief Executive Officer |
Robert Baffi | President of Global Manufacturing and Technical Operations |
Jeff Ajer | Executive Vice President and Chief Commercial Officer |
Henry Fuchs | President, Worldwide Research and Development |
Brian Mueller | Acting Chief Financial Officer |
Robyn Karnauskas | SunTrust Robinson Humphrey Inc |
Salveen Richter | Goldman Sachs |
Joshua Schimmer | Evercore ISI |
Cory Kasimov | JPMorgan |
Geoffrey Meacham | Bank of America Merrill Lynch |
Akash Tewari | Wolfe Research, LLC |
Christopher Raymond | Piper Sandler |
Philip Nadeau | Cowen and Company |
Matthew Harrison | Morgan Stanley |
Alex Thompson | Stifel Nicolaus |
Mohit Bansal | Citigroup |
Tim Lugo | William Blair & Company, L.L.C. |
Kennen MacKay | RBC Capital Markets |
Peter Kim | Barclays Capital |
Eliana Merle | Cantor Fitzgerald |
Vincent Chen | Bernstein Research |
Welcome to the BioMarin First Quarter 2020 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Tracy.
Thank you, May, and thank you, everyone, for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin, including expectations, regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development.